| INTRODUCTION
Atopic dermatitis (AD), contact dermatitis (CD), and psoriasis (PS) are common relapsing inflammatory skin diseases characterized by significant epidermal disruption, local and systemic inflammation, and impaired quality-of-life. Diseases have been extensively investigated; however, their similarities and differences are not fully understood which can complicate diagnosis and treatment.
AD affects approximately 25% of children and 10% of adults 1, 2 and is primarily associated with an increased T helper (Th) 2 inflammatory response, which modulates the epidermal barrier and innate immune response permitting enhanced penetration of allergens and pathogens. 3, 4 CD results from skin exposure to allergens or irritating chemicals and is a significant co-morbidity in approximately 40% of patients with AD, potentially because of epidermal barrier disruption that contributes to impaired protection. [5] [6] [7] [8] Clinical manifestations of CD can mimic AD, making it challenging to distinguish these diseases. PS affects approximately 3% of the population [9] [10] [11] and is characterized by recurrent episodes of red and scaly skin plaque which develop as a result of aberrant keratinocyte proliferation, differentiation, and immune infiltration.
Genome-wide studies demonstrate a significant overlap between the susceptibility loci for AD and PS 12, 13 suggesting potential overlapping pathogenic mechanisms. The significant physical, psychological, and economical quality-of-life impairment associated with these diseases drives the importance of correct diagnosis and effective therapy. [14] [15] [16] Extensive gene expression and immune cell profiling have revealed that AD is predominantly Th2/Th22 polarized, with some Th17 involvement. 17 Progression of AD is associated with activation of Th2-defining cytokines, such as interleukin (IL)-4, IL-13, thymic stromal lymphopoietin, and IL-31, as well as Th22-defining cytokines, such as IL-22. [18] [19] [20] [21] Further, increased Th2/Tc2/IL-13 + and Th22/ Tc22/IL-22 + cell population were observed in patients with severe AD. 22 PS deviates towards Th17 and Th1 responses, with the IL-23/ Th17 axis playing a critical role in the pathogenesis. IL-23 drives production of IL-17 from Th17 cells, which activates keratinocytes, and induces synthesis of pro-inflammatory chemokines, such as C-X-C motif ligand (CXCL) 1, CXCL2, CXCL3, and CXCL8. [23] [24] [25] CD was historically considered a Th1-dominated or a mixed Th1/Th2 response; however, it is increasingly recognized that Th17 and Th22 cytokines also contribute to disease progression. [26] [27] [28] [29] A recent gene expression profiling study showed that the immune systems of patients with CD are differentially activated depending on different allergens, 30 suggesting overlap with other inflammatory diseases.
While gene expression analysis in skin biopsies has resulted in a greater understanding of mechanisms underlying disease and potential biomarkers, 31 there is still a need for a non-invasive method to distinguish between inflammatory diseases. Serum protein profiling is emerging as a powerful complementary approach to genomic analysis of skin biopsies. Serum collection is minimally invasive and, combined with broad proteomic approaches, can provide access to important biomarkers of systemic inflammation. Additionally, protein concentrations may better reflect the function and dynamics of cells enabling targeted therapy to address systemic inflammation.
In this study, we utilized broad proteomic approaches to characterize serum protein profiles in subjects with active AD, CD, and PS compared with healthy controls (HC Table S1 . No significant difference for genders (Chi-square test), but significant difference for age (ANOVA, P value<0.05), was detected between different groups. Therefore, age was fitted as numerical covariate for analysis (details see "Section 2.6" below).
Atopic dermatitis subjects were further separated based on total serum IgE levels (ImmunoCAP) into intrinsic AD (IgE<200 U/mL, N=6) or extrinsic AD (IgE≥200 U/mL, N=14). Additionally, CD was confirmed in subjects by patch-testing for the 15 most common allergens of the North American Contact Dermatitis Group and petrolatum-occluded skin (as control). At 72 hours, the patch test site was evaluated for reactivity, and positive reactions were clinically graded as 1+, 2+, or 3+.
These studies were conducted according to the Declaration of the Helsinki Guidelines and were approved by the institutional review board at Icahn School of Medicine at Mount Sinai (#HS 14-00436; GCO#1: 14-0863 (0001) Icahn School of Medicine) in New
York. All subjects gave written informed consent prior to enrolment.
Additionally, subjects confirmed the absence of comorbidities such as asthma, allergic rhinitis, diabetes, cardiovascular pathologies, or self-reported history of systematic inflammatory disorders.
| Epidermal thickness
Epidermal thickness was quantified as previously described 32 using
computer-assisted image analysis software (ImageJ 1.42; National
Institutes of Health, Bethesda, MD, USA). The epidermal thickness measurement included all layers, including the stratum corneum.
| Serum collection
Blood samples were collected using BD Vacutainer Plus plastic serum tubes. After collection, blood was allowed to clot by leaving Values are reported in relative fluorescence units (RFU).
| Serological measurement of IgE and inflammatory mediators
The levels of total serum IgE were determined using ImmunoCAPradioallergosorbent test (RAST) system (ThermoScientific; Uppsala, Briefly, after blocking the plate well, the serum is added and incubated for 2 hours and chemiluminescence determined using the Sector Imager Reader (Meso Scale Discovery).
| Statistical analysis
Prior to analysis, RFU values from SOMAscan TM assays were normalized against hybridization control sequences to correct for any systematic effects introduced during hybridization. Median normalization was performed across samples within an array. Calibration was performed using samples in each array to allow comparison across runs. 35 To reduce heteroscedasticity, values were log2 transformed. Protein expression was modelled using a linear model with age as numerical covariate and disease as factor covariate; parameters were estimated using the empirical Bayes method (Smyth, 2004) available in the Limma package in R. 36 This approach allows us to obtain estimates of disease effect, adjusting for the potential impact of age. The age-coefficients can be used to adjust the protein expression accordingly. Default parameters were used, except the "proportion" parameter was set to 0.05. Between groups comparisons were assessed using contrast and the P-values of the moderated t test were adjusted by the Benjamini-Hochberg procedure which controls the false discovery rate (FDR). Differentially expressed proteins were defined as those with fold change (FCH)≥1.5 and FDR≤0.05. Correlation analysis was performed with
Pearson correlation test or Spearman correlation test (when normal distribution of the data cannot be guaranteed). Results were summarized using Venn diagrams and heatmaps using R capabilities. Scatter plots and correlation plots were generated with GraphPad Prism6.
Functional annotation of protein targets is performed using DAVID (https://david.ncifcrf.gov/tools.jsp) and Ingenuity Pathway Analysis (http://www.ingenuity.com/products/ipa).
| RESULTS
We evaluated the reproducibility of the SOMAscan (Table S2) . Figure 1A , B, Table S3 ). The proteomic signature for AD was refined by comparing proteomic modulation with CD and PS. IgE, TARC, and MDC showed significant upregulation in AD alone compared with CD and PS ( Figure 3A , Table S4 ), suggesting these three inflammatory mediators as a signature of AD. No unique proteins were found to be significantly down-regulated in AD alone.
As mentioned above, the detection of TARC, MDC, and IgE by SOMAscan platform was confirmed by ECL Plex fluorescent Western blotting from serum samples of the same AD subjects. For all three proteins, the Spearman correlation coefficient between the two platforms was approximately 0.97 (P<0.05) ( Figure 3B and Table S2 ).
We further explored the relationship between expression of these three proteins and SCORAD disease severity. for MDC, P<0.01) (Fig. S1 ).
| Proteomic signature identification in contact dermatitis
Proteomic analysis detected 24 proteins with significant upregulation and 40 proteins with significant downregulation in CD compared with HC ( Figure 1A , B, Table S5 ). We further refined the protein signature associated with CD by comparing with AD and PS to detect significant upregulation of bone morphogenetic protein 14 (BMP-14), BMP-7, lactadherin (MFGM), polymeric immunoglobulin receptor (PIGR), albumin, a2-Macroglobulin and growth/differentiation factor 2 (GDF2) ( Figure 4A and Table S5 ) and downregulation of 14 proteins outlined in Fig. S2 and Table S5 .
| KYNU modulation is unique to psoriasis
Kynureninase (KYNU), lectin galactoside-binding soluble 3-binding protein (LG3BP), and tryptase beta-2 (TPSB2) were significantly increased, and carbonic anhydrase 6 (CA6) was significantly decreased in PS compared with HC (Table S6) . Among these proteins, KYNU also showed significant upregulation when comparing PS with AD and CD ( Figure 4B and Table S6 ) suggesting its utility as a biomarker for PS. KYNU expression has been reported to be up-regulated in psoriasis in multiple transcriptomic studies and was reported as one of the 20 signature genes that discriminate between lesion and non-lesion skin. [38] [39] [40] [41] [42] [43] Our study demonstrates that increased KYNU in circulation can also discriminate individuals with active PS Interestingly, no significant correlation was observed between concentrations of KYNU and disease PASI score (P=0.67, r=0.14).
3.5 | Novel proteins are associated with subjects with both AD and contact dermatitis
In our study, 10 subjects had clinical manifestations of CD and a history of AD (AD+CD). Given the heterogeneity of disease, we compared protein concentrations of the subjects with both AD+CD with HC ( Figure 5A-C) . The proteomic profile in AD+CD subjects was similar to subjects with CD, while a greater level of protein dysregulation was observed (Table S7 and Figure 5C ). A total of 68 proteins showed significant upregulation in subjects with AD+CD and lesions. In some instances, similarities make it challenging to distinguish between the diseases. Previous approaches to characterize and differentiate these diseases focused on transcriptomic profiling of skin biopsies. 18, 44, 45 While this increased our mechanistic understanding of each disease, the invasive nature of skin biopsies prevents it from being incorporated into routine clinical practice.
Additionally, upregulation of gene transcript does not always result into translation of protein. Recent studies demonstrate that these diseases are characterized by systemic inflammation which may provide the opportunity to non-invasively distinguish diseases through evaluation of circulating proteomic signatures. [44] [45] [46] Using broad proteomic analysis of sera from well-characterized subject cohorts, we identified unique proteomic signatures for AD, CD, and PS. Interestingly, several proteins were elevated in all three skin diseases suggesting that local barrier disruption may trigger similar inflammatory activation in circulation. Specifically, a circulating signature of PARC (CCL18), C5A, LBP, CRP, ILT-4, and SIG14 was identified in all three diseases. PARC is a dendritic cell-derived chemokine up-regulated in AD that mediates skin homing of human memory T cells. [47] [48] [49] Furthermore, significant decrease of PARC was observed in AD after immunotherapy. 50, 51 Increased gene expression of PARC was reported in PS, although to a lesser extent than AD. 52 This is consistent with our observations; we also showed upregulation of PARC in CD. CRP is produced in response to inflammation. Interestingly, the TRAF1-C5 locus has been identified in multiple studies as a genetic risk factor for autoimmune diseases such as rheumatoid arthritis, type I diabetes, and systemic lupus erythematosus. [56] [57] [58] [59] [60] LBP is involved in the acute-phase immunologic response to Gram-negative bacterial infections and shows increased concentrations in multiple autoimmune diseases, including arthritis and chronic obstructive pulmonary disease. 61, 62 SIG14 is a paired receptor with SIG5 and is believed to mediate signalling in neutrophils and macrophages in innate immune responses. 63 Interestingly, ILT-4 is generally considered an immune inhibitory factor that mediates the function of regulatory and suppressive T cells [64] [65] [66] [67] [68] ; the mechanism of its upregulation and function in these diseases remains to be explored. Overall, upregulation of these proteins in all three diseases supports the critical role of the innate immune system in the pathogenesis of these diseases.
Although the pathogenic mechanisms are not fully understood, have shown significant elevations of these Th2 cytokine genes in lesional AD skin 21, 37 ; however, there is conflicting information on the levels of these cytokines in circulation of adult patients with AD as many platforms lack sensitivity necessary for accurate measurements. Recently, periostin was identified as a potential surrogate for IL-4 and IL-13 signalling and activation. 69 In our study, we observed with PS compared with AD. 90 In this study, we observed increased body mass index (BMI) scores in the patients with PS compared with AD. Therefore, the observed elevation may be due to an increase in BMI rather than disease pathogenesis, although no significant correlation was observed between KYNU and BMI in patients with PS (data not shown).
Atopic dermatitis and CD are both characterized by significant epidermal barrier disruption and epithelial inflammation. Recently, several studies have demonstrated overlapping transcriptomic signatures in the lesional skin of AD and CD subjects. 30, 44 Additional characterization by the investigators identified unique transcriptomic profiles in the skin that corresponded with different sensitization profiles. In our cohort, 10 subjects displayed symptoms of both AD and CD, which accounts for 33% of all patients with AD and 50% of all patients with CD. Given the potential differences in their sensitization profiles, we hypothesized that subjects with both AD and CD would have a distinct proteomic signature independent from both AD and CD. Importantly, the subjects with AD and CD display novel dysregulated proteins, 91, 92 especially upregulation of immune-related proteins.
In conclusion, we present the first high-throughput proteomic profiling across AD, PS, and CD using SOMAscan not show significant difference between disease subjects and healthy controls. As more proteins are added to this and other assays, it will be important to confirm the sensitivity of both the assay and targets using independent approaches. This will further validate the identification and use of proteomic signatures with patient populations. It will also be important to extend the analysis to larger patient populations and perform mechanistic studies to understand the function of these proteins in disease pathogenesis.
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